Periodic Reporting for period 1 - MagnoBeads (Removing endotoxins during sepsis: a blood purification platform using magnetic nanoparticles)
Reporting period: 2018-12-01 to 2019-05-31
Sepsis is a dysregulated immune response to infection and affects 19 million people each year. With a mortality rate of >30% for septic shock it is the most common cause of death in intensive care units. Currently, no effective cure for sepsis exits, and treatment focuses on infection control (antimicrobial agents) and supportive care (fluid resuscitation, vasopressors, ventilators and hemodialysis). Therefore, a huge societal need and market opportunity exist for curative sepsis treatments.
hemotune Ltd is a spin-off company of ETH Zurich, founded to commercialize blood purification technology for the treatment of septic shock. Hemotune is developing a blood filtration device that removes toxic particles from the blood, by employing magnetic nanoparticles that selectively bind toxic molecules and then removing them from the blood by a magnetic filter (see figure). This technology was successfully tested in small-scale animal models.
hemotune Ltd is a spin-off company of ETH Zurich, founded to commercialize blood purification technology for the treatment of septic shock. Hemotune is developing a blood filtration device that removes toxic particles from the blood, by employing magnetic nanoparticles that selectively bind toxic molecules and then removing them from the blood by a magnetic filter (see figure). This technology was successfully tested in small-scale animal models.
In the MagnoBeads project, the technical and commercial feasibility of the technology were extensively evaluated. Insights were obtained regarding prototype upscaling, usability to a human scale, regulatory barriers, IP strategy and the go-to-market strategy. Based on the feasibility study, it was concluded that hemotune’s technology is both technically and commercially feasible. Moreover, technical and commercial risks were identified for which mitigation measures can now be incorporated in the business strategy.
As a result of the MagnoBeads project, the hemotune business plan significantly matured. Based on the feasibility studies, the company has the instruments to attract further funding to finance further development to bring its technology towards the clinic. Ultimately, hemotune's technology has the potential to improve prospects for annually >300k patients suffering from septic shock in the seven main markets.